ReviewNeurosurgery clinics of North America2021
Targeting Glioma Stem Cells.
Review in Neurosurgery clinics of North America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Exosome-Mediated Bidirectional Signaling Regulates Glioma Stem-Cell Homeostasis and Radiation-Induced Plasticity.bioRxiv : the preprint server for biology · 2026Article
- TRIM21 functions as an oncogene in glioblastoma by transactivating FOSL1 and promoting the ubiquitination of p27.Cell communication and signaling : CCS · 2025Article
- FDFT1 maintains glioblastoma stem cells through activation of the Akt pathway.Stem cell research & therapy · 2024Article
- Review
- The Role of Non-Coding RNAs in Epigenetic Dysregulation in Glioblastoma Development.International journal of molecular sciences · 2023Review
- Pathogenesis Study of Glioma: From Glioma Stem Cells, Genomic Tags, to Rodent Models.Brain sciences · 2022Article
- Mechanism of RIP2 enhancing stemness of glioma cells induces temozolomide resistance.CNS neuroscience & therapeutics · 2022Article
- Immunotherapeutic Approaches for Glioblastoma Treatment.Biomedicines · 2022Review
- Uridine-cytidine kinase 2 promotes glycolysis and reprograms glioblastoma stem cell characteristics under hypoxic conditions through the PI3K/Akt/HIF-1α pathway.Cell cycle (Georgetown, Tex.)Article
- OLIG2-STAT5 cooperation supports glioma stem cell maintenance and proliferation in glioblastoma.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Only a small fraction of the tumor cell population, glioma-initiating cells (GICs) help glioblastoma propagate, invade, evade immune recognition, repair DNA in response to radiation more efficiently, remodel the microenvironment for optimal growth, and actively pump out chemotherapies. Recent data hint that efforts toward GIC characterization and quantification can help predict patient outcomes, and yet the different subpopulations of GICs remain incompletely understood. A better understanding of GIC subtypes and functions proves critical for engineering targeted therapies. Challenges for doing so are discussed, and dopamine receptor antagonists are introduced as new means to enhance the efficacy of the current standard-of-care against GICs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.